Shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) shot up 0% during mid-day trading on Wednesday . The stock traded as high as $0.97 and last traded at $0.90. 1,260,499 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 1,079,899 shares. The stock had previously closed at $0.90.

The stock has a market cap of $28.67, a price-to-earnings ratio of -0.85 and a beta of 3.04.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Municipal Employees Retirement System of Michigan acquired a new stake in Eleven Biotherapeutics in the third quarter valued at $382,000. Virtu KCG Holdings LLC acquired a new stake in Eleven Biotherapeutics in the second quarter valued at $175,000. Finally, Vanguard Group Inc. raised its holdings in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 30,600 shares in the last quarter. 3.84% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Eleven Biotherapeutics (EBIO) Shares Up 0%” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with's FREE daily email newsletter.